This R01 application is in response to RFA-DE-07-002 to study the long-term use of antiretroviral therapy (ART) on the oral mucosa. Specifically, we will investigate how changes in the oropharyngeal tissues contribute to the pathogenesis of the human herpes viruses HSV-1, EBV and KSHV. These human pathogens cause different disease phenotype ranging from tissue destructive viremia (HSV-1) to oral cancer (KSHV, EBV). Regardless though of the final pathology, reactivation from a viral latent state seems to precede disease, and in case of EBV and KSHV many of the disease phenotypes are caused by gene products that are only expressed during viral reactivation. We hypothesize that (a) changes in the oral mucosal epithelial surfaces cause virus reactivation and (b) that ART modulates both the physiological trigger and the viral gene profile leading to ART-associated viral diseases such as oral KS, which is hardly seen in HIV-negative, ART-negative so called classic KS patients or EBV-positive plasmablastic lymphomas of the lower jaw. Furthermore, we will explore the effect of ART drugs on the innate immune response, i.e. TLR signaling by using our recently developed NF-kappaB real-time QPCR array to compare both clinical samples and experimental models of buccal and gingival epithelium.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE018304-03
Application #
7609198
Study Section
Special Emphasis Panel (ZDE1-PZ (19))
Program Officer
Rodriguez-Chavez, Isaac R
Project Start
2007-05-15
Project End
2012-04-30
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
3
Fiscal Year
2009
Total Cost
$317,667
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sin, Sang-Hoon; Eason, Anthony B; Bigi, Rachele et al. (2018) Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections. J Virol 92:
Zhang, Yugen; Dittmer, Dirk P; Mieczkowski, Piotr A et al. (2018) RIG-I Detects Kaposi's Sarcoma-Associated Herpesvirus Transcripts in a RNA Polymerase III-Independent Manner. MBio 9:
Lee, Jennifer S; Cole, Stephen R; Achenbach, Chad J et al. (2018) Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS One 13:e0197665
Selitsky, Sara R; Marron, David; Mose, Lisle E et al. (2018) Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. mSystems 3:
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Bigi, Rachele; Landis, Justin T; An, Hyowon et al. (2018) Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 115:E11379-E11387
Hopcraft, Sharon E; Pattenden, Samantha G; James, Lindsey I et al. (2018) Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog 14:e1007267
Schneider, Johann W; Dittmer, Dirk P (2017) Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol 18:529-539
Host, Kurtis M; Jacobs, Sarah R; West, John A et al. (2017) Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. MBio 8:
Angius, Fabrizio; Piras, Enrica; Uda, Sabrina et al. (2017) Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation. J Antibiot (Tokyo) 70:962-966

Showing the most recent 10 out of 74 publications